Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-08-13), Elevance Health's 1-Year Sharpe Ratio is 0.45.
Elevance Health (MEX:ELV) 1-Year Sharpe Ratio Explanation
The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.
The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.
Elevance Health 1-Year Sharpe Ratio Related Terms
MEX:ELV vs CI, HUM, CNC: 1-Year Sharpe Ratio Comparison
For the Healthcare Plans subindustry, Elevance Health's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elevance Health 1-Year Sharpe Ratio vs Healthcare Plans Industry
For the Healthcare Plans industry and Healthcare sector, Elevance Health's 1-Year Sharpe Ratio distribution charts can be found below:
* The bar in red indicates where Elevance Health's 1-Year Sharpe Ratio falls into.
The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.
Elevance Health (MEX:ELV) has a 1-Year Sharpe Ratio of 0.45 as of Aug. 13, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Elevance Health and its competitors.
Is Elevance Health's 1-Year Sharpe Ratio too high?
Elevance Health's current 1-Year Sharpe Ratio is 0.45. Overall, Elevance Health has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Elevance Health's 1-Year Sharpe Ratio compare to CI and HUM?
Elevance Health's 1-Year Sharpe Ratio of 0.45 can be compared against companies in the Healthcare Plans industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Healthcare Plans company?
A good 1-Year Sharpe Ratio depends on the Healthcare Plans industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Elevance Health and its competitors. Elevance Health's current 1-Year Sharpe Ratio is 0.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elevance Health stock overvalued right now?
Based on GuruFocus' analysis, Elevance Health (MEX:ELV) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN7,822.04, compared to a current price of MXN6,449.00 — trading 17.6% below its estimated fair value. The current 1-Year Sharpe Ratio is 0.45. Elevance Health's overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Elevance Health (MEX:ELV), the current 1-Year Sharpe Ratio is 0.45 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Elevance Health (MEX:ELV) Overvalued in 2026?
Based on GuruFocus' analysis, Elevance Health stock appears to be undervalued.
The current stock price of MXN6,449.00 is trading 17.6% below its estimated GF Value™ of MXN7,822.04.
GuruFocus considers Elevance Health to be Modestly Undervalued.
Key valuation signals for MEX:ELV:
1-Year Sharpe Ratio: 0.45
GF Value™: MXN7,822.04 vs. price of MXN6,449.00 (17.6% below fair value)
No single metric tells the full story. See the MEX:ELV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Elevance Health remains one of the leading health insurers in the US, providing medical benefits to 45 million medical members at the end of 2025. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states in government-sponsored programs, such as Medicaid and Medicare Advantage plans, too. It is also an emerging player in pharmacy benefit management and other healthcare services.
75GF Score
Get the complete analysis for MEX:ELV
1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ELV has been successfully added to your 
